LEGN Legend Biotech Corporation
$19.11
Legend Biotech Corporation (LEGN) is expected to report earnings on November 16, 2026, before the market open. The consensus earnings estimate is $0.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.2% since its last earnings release on August 11, 2026.
Legend Biotech Missed Expectations
Tuesday, August 11, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 7:00 AM ET
Earnings Whisper
-
vs $0.01
Rev est $355.26M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$19.91
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Legend Biotech Corporation
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications.
Sector
Healthcare
Industry
Biotechnology
Held By 14 ETFs, by dollar flow
- IPO Renaissance IPO ETF
- IPO Renaissance IPO ETF
- IXUS iShares Core MSCI Total International Stock ETF
- IXUS iShares Core MSCI Total International Stock ETF
- ACWX iShares MSCI ACWI ex U.S. ETF
- ACWX iShares MSCI ACWI ex U.S. ETF
- IEMG iShares Core MSCI Emerging Markets ETF
- IEMG iShares Core MSCI Emerging Markets ETF
- EEM iShares MSCI Emerging Markets ETF
- EEM iShares MSCI Emerging Markets ETF
- GXC SPDR S&P China ETF
- GXC SPDR S&P China ETF
- MCHI iShares MSCI China ETF
- MCHI iShares MSCI China ETF
Charts powered in part by Lightweight Charts™ by TradingView.